David Nierengarten
Stock Analyst at Wedbush
(4.55)
# 322
Out of 5,182 analysts
233
Total ratings
58.71%
Success rate
19.5%
Average return
Main Sectors:
Stocks Rated by David Nierengarten
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CATX Perspective Therapeutics | Reiterates: Outperform | $11 | $4.72 | +133.05% | 7 | Apr 20, 2026 | |
| KNSA Kiniksa Pharmaceuticals International, | Maintains: Outperform | $53 → $58 | $43.09 | +34.60% | 7 | Apr 16, 2026 | |
| NVCR NovoCure | Reiterates: Neutral | $18 | $12.99 | +38.57% | 10 | Apr 16, 2026 | |
| NUVB Nuvation Bio | Reiterates: Outperform | $11 | $5.21 | +111.34% | 15 | Apr 16, 2026 | |
| FENC Fennec Pharmaceuticals | Reiterates: Outperform | $13 | $6.60 | +96.97% | 4 | Apr 16, 2026 | |
| SYRE Spyre Therapeutics | Maintains: Outperform | $65 → $80 | $73.54 | +8.78% | 2 | Apr 14, 2026 | |
| TLX Telix Pharmaceuticals | Reiterates: Outperform | $22 | $10.30 | +113.59% | 5 | Apr 13, 2026 | |
| NUVL Nuvalent | Reiterates: Outperform | $125 | $108.24 | +15.48% | 7 | Apr 8, 2026 | |
| ORIC ORIC Pharmaceuticals | Maintains: Outperform | $20 → $17 | $10.51 | +61.75% | 11 | Apr 1, 2026 | |
| SRRK Scholar Rock Holding | Maintains: Outperform | $56 → $58 | $47.59 | +21.87% | 8 | Apr 1, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $30 | $23.19 | +29.37% | 4 | Mar 31, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $55 | $37.13 | +48.13% | 5 | Mar 17, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $1,000 | $795.27 | +25.74% | 25 | Mar 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $4 → $8 | $7.54 | +6.12% | 2 | Mar 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $4 → $5 | $1.25 | +300.00% | 5 | Mar 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $90 → $95 | $91.07 | +4.32% | 4 | Mar 3, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $57 → $65 | $31.63 | +105.50% | 4 | Feb 25, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Underperform | $110 | $115.51 | -4.77% | 1 | Feb 24, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $110 → $88 | $69.19 | +27.19% | 5 | Feb 17, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $31 | $23.86 | +29.95% | 7 | Jan 15, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $25 | $8.58 | +191.38% | 3 | Dec 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $9 → $7 | $16.31 | -57.08% | 11 | Nov 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $5 → $7 | $1.37 | +410.95% | 16 | Oct 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $26 | $12.90 | +101.55% | 8 | Sep 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $8 | $15.51 | -48.42% | 8 | Jun 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $80 → $20 | $34.50 | -42.03% | 7 | Mar 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 | $52.11 | -23.24% | 13 | Feb 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $40 | $69.03 | -42.05% | 1 | Sep 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $18 | $10.84 | +66.02% | 1 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $12 | $3.90 | +207.69% | 3 | Apr 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $1,400 → $500 | $1.62 | +30,854.00% | 1 | Dec 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $105 → $60 | $9.59 | +525.65% | 7 | Jul 26, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $71 → $75 | $24.44 | +206.87% | 8 | Feb 14, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $1.58 | - | 3 | Dec 3, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $4.18 | - | 2 | May 11, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $10.76 | - | 3 | Nov 20, 2017 |
Perspective Therapeutics
Apr 20, 2026
Reiterates: Outperform
Price Target: $11
Current: $4.72
Upside: +133.05%
Kiniksa Pharmaceuticals International,
Apr 16, 2026
Maintains: Outperform
Price Target: $53 → $58
Current: $43.09
Upside: +34.60%
NovoCure
Apr 16, 2026
Reiterates: Neutral
Price Target: $18
Current: $12.99
Upside: +38.57%
Nuvation Bio
Apr 16, 2026
Reiterates: Outperform
Price Target: $11
Current: $5.21
Upside: +111.34%
Fennec Pharmaceuticals
Apr 16, 2026
Reiterates: Outperform
Price Target: $13
Current: $6.60
Upside: +96.97%
Spyre Therapeutics
Apr 14, 2026
Maintains: Outperform
Price Target: $65 → $80
Current: $73.54
Upside: +8.78%
Telix Pharmaceuticals
Apr 13, 2026
Reiterates: Outperform
Price Target: $22
Current: $10.30
Upside: +113.59%
Nuvalent
Apr 8, 2026
Reiterates: Outperform
Price Target: $125
Current: $108.24
Upside: +15.48%
ORIC Pharmaceuticals
Apr 1, 2026
Maintains: Outperform
Price Target: $20 → $17
Current: $10.51
Upside: +61.75%
Scholar Rock Holding
Apr 1, 2026
Maintains: Outperform
Price Target: $56 → $58
Current: $47.59
Upside: +21.87%
Mar 31, 2026
Reiterates: Outperform
Price Target: $30
Current: $23.19
Upside: +29.37%
Mar 17, 2026
Reiterates: Outperform
Price Target: $55
Current: $37.13
Upside: +48.13%
Mar 9, 2026
Reiterates: Outperform
Price Target: $1,000
Current: $795.27
Upside: +25.74%
Mar 6, 2026
Maintains: Outperform
Price Target: $4 → $8
Current: $7.54
Upside: +6.12%
Mar 5, 2026
Maintains: Outperform
Price Target: $4 → $5
Current: $1.25
Upside: +300.00%
Mar 3, 2026
Maintains: Outperform
Price Target: $90 → $95
Current: $91.07
Upside: +4.32%
Feb 25, 2026
Maintains: Outperform
Price Target: $57 → $65
Current: $31.63
Upside: +105.50%
Feb 24, 2026
Initiates: Underperform
Price Target: $110
Current: $115.51
Upside: -4.77%
Feb 17, 2026
Maintains: Outperform
Price Target: $110 → $88
Current: $69.19
Upside: +27.19%
Jan 15, 2026
Reiterates: Outperform
Price Target: $31
Current: $23.86
Upside: +29.95%
Dec 11, 2025
Reiterates: Outperform
Price Target: $25
Current: $8.58
Upside: +191.38%
Nov 7, 2025
Maintains: Neutral
Price Target: $9 → $7
Current: $16.31
Upside: -57.08%
Oct 27, 2025
Upgrades: Outperform
Price Target: $5 → $7
Current: $1.37
Upside: +410.95%
Sep 2, 2025
Reiterates: Outperform
Price Target: $26
Current: $12.90
Upside: +101.55%
Jun 26, 2025
Reiterates: Neutral
Price Target: $8
Current: $15.51
Upside: -48.42%
Mar 14, 2025
Downgrades: Neutral
Price Target: $80 → $20
Current: $34.50
Upside: -42.03%
Feb 7, 2025
Maintains: Outperform
Price Target: $40
Current: $52.11
Upside: -23.24%
Sep 4, 2024
Initiates: Outperform
Price Target: $40
Current: $69.03
Upside: -42.05%
Aug 13, 2024
Initiates: Outperform
Price Target: $18
Current: $10.84
Upside: +66.02%
Apr 23, 2024
Reiterates: Outperform
Price Target: $12
Current: $3.90
Upside: +207.69%
Dec 8, 2023
Maintains: Equal-Weight
Price Target: $1,400 → $500
Current: $1.62
Upside: +30,854.00%
Jul 26, 2023
Maintains: Neutral
Price Target: $105 → $60
Current: $9.59
Upside: +525.65%
Feb 14, 2020
Maintains: Outperform
Price Target: $71 → $75
Current: $24.44
Upside: +206.87%
Dec 3, 2019
Downgrades: Neutral
Price Target: n/a
Current: $1.58
Upside: -
May 11, 2018
Upgrades: Outperform
Price Target: n/a
Current: $4.18
Upside: -
Nov 20, 2017
Downgrades: Neutral
Price Target: n/a
Current: $10.76
Upside: -